2 completed, 1 active not recruiting, 1 not yet recruiting, 1 terminated. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 2, Active not recruiting 1, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
Follow CTCL: new trials by email Literature Review of CTCL trials Research Report on CTCL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma FG-M131 - PTCL, TRBC1 ADC | Phase 1 / Phase 2 | Not yet recruiting | FutureGen Biopharmaceutical (Beijing) Co., Ltd | 110 | 2026-08-30 | 2026-09-02 |
| Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL Pembrolizumab, Pralatrexate, Decitabine - PTCL, CTCL | Phase 1 | Active not recruiting | University of Virginia | 37 | 2022-02-02 | 2026-04-07 |
| A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL) ABT-199 (venetoclax) - CTCL | Phase 1 | Completed | Yale University | 4 | 2020-01-15 | 2021-06-25 |
| A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL BNZ132-1-40 - LGL Leukemia, CTCL | Phase 1 / Phase 2 | Completed | Bioniz Therapeutics | 50 | 2018-04-01 | 2021-05-25 |
| Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL Volasertib, Romidepsin - PTCL, CTCL | Phase 1 | Withdrawn | Anne Beaven, MD | 2016-11-01 | 2016-12-01 | |
| A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors MEDI9197, durvalumab - Solid Tumors, CTCL | Phase 1 | Terminated | MedImmune LLC | 53 | 2015-11-04 | 2018-12-19 |
Leukemia, Large Granular Lymphocytic (1) · Lymphoma, T-Cell (1) · Neoplasms (1)
Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Leukemia, T-Cell (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1)
10-propargyl-10-deazaaminopterin (1) · BI 6727 (1) · Decitabine (1) · MEDI9197 (1) · durvalumab (1) · pembrolizumab (1) · romidepsin (1) · venetoclax (1)
Anne Beaven, MD (1) · Bioniz Therapeutics (1) · FutureGen Biopharmaceutical (Beijing) Co., Ltd (1) · MedImmune LLC (1) · University of Virginia (1) · Yale University (1)
United States (4) · Canada (1) · China (1) · France (1)
Enrica Marchi, MD, PhD (1) · Jonathan Brammer, MD, PhD (1) · Michael Girardi, MD, FAAD (1) · Owen O'Connor, MD, PhD (1)